Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Recurrent/Metastatic Invasive Breast Carcinoma
NCT00509587Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Partial and Complete Response up to 3 years. Started Jun 2007; status: completed.
02
Drugs
pazopanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00509587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509587.